
KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer
Due to its amplification in approximately 12% to 15% of patients with estrogen receptor (ER)–positive breast cancer and ability to repress ER gene transcription, thereby overcoming ESR1-mediated resistance to endocrine therapy, KAT6 had garnered attention …